US4681897A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Pharmaceutical products providing enhanced analgesia
Assignee: Procter and Gamble Co
•
Filing: 1984-12-24
•
Granted: 1987-07-21
•
Expires: 2004-12-24
Abstract
Abstract An analgesic composition comprising capsaicin or a capsaicin analogue and an analgesic selected from the class of non-steroidal anti-inflammatory, antipyretic and analgesic drugs is disclosed. This combination has been found to exhibit unexpectedly enhanced analgesic activity in humans and lower animals without a corresponding increase in undesirable side effects.
Inventors
- 👤 Larry M. Brand
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-26 20:35
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/185; A61K31/19; A61K31/16; A61K31/165; A61K31/60; A61K31/618; A61K31/621; A61K45/00; A61K45/06; A61P; A61P25/00; A61P25/04
Claims Analysis
Total Claims: 17
Claim 1
Independent Claim
92 words
An analgesic composition comprising a safe and effective amount of: (a) a capsaicinoid analgesic compound of the general formula: ##STR8## wherein R 1 is selected from the group consisting of OH and OCH 3 , X is selected from the group consisting of ##STR9## and R is a C 16 -C 21 cis-monounsaturated alkenyl; (b) a nonsteroidal analgesic selected from the group consisting of ibuprofen, naproxen, ketoprofen, fenaprofen, suprofen, flurbiprofen, benoxaprofen, perprofen, and carprofen; and (c) a pharmaceutically-acceptable carrier; wherein the weight ratio of (a):(b) is from about 20:1 to about 1:20.
Claim 2
Dependent Claim
92 words
An analgesic composition comprising a safe and effective amount of: (a) a capsaicinoid analgesic compound of the general formula: ##STR8## wherein R 1 is selected from the group consisting of OH and OCH 3 , X is selected from the group consisting of ##STR9## and R is a C 16 -C 21 cis-monounsaturated alkenyl; (b) a nonsteroidal analgesic selected from the group consisting of ibuprofen, naproxen, ketoprofen, fenaprofen, suprofen, flurbiprofen, benoxaprofen, perprofen, and carprofen; and (c) a pharmaceutically-acceptable carrier; wherein the weight ratio of (a):(b) is from about 20:1 to about 1:20.
Claim 3
Dependent Claim
19 words
A composition according to claim 1, wherein the weight ratio of (a):(b) is from about 10:1 to about 1:10.
Claim 4
Dependent Claim
15 words
A composition according to claim 2, wherein R 1 is OH and X is ##STR10##
Claim 5
Dependent Claim
13 words
A composition according to claim 2, wherein R 1 is OCH 3 .
Claim 6
Dependent Claim
10 words
A composition according to claim 4, wherein X is ##STR11##
Claim 7
Dependent Claim
14 words
A composition according to claim 5, wherein R is C 17 H 33 .
Claim 8
Dependent Claim
11 words
A composition according to claim 1, wherein the non-steroidal is ibuprofen.
Claim 9
Dependent Claim
21 words
A composition according to claim 7, wherein the weight ratio of capsaicinoid to ibuprofen is from about 5:1 to about 1:5.
Claim 10
Dependent Claim
11 words
A composition according to claim 8 wherein the capsaicinoid is N-vanillyl-9Z-octadecenamide.
Claim 11
Dependent Claim
11 words
A composition according to claim 1, wherein the non-steroidal is naproxen.
Claim 12
Independent Claim
109 words
A method for providing analgesia in humans and lower animals which comprises administering concurrently to a human or lower animal in need of such treatment a safe and effective amount of: (a) a capsaicinoid analgesic compound of the general formula: ##STR12## wherein R 1 is selected from the group consisting of OH and OCH 3 , X is selected from the group consisting of ##STR13## and R is a C 16 -C 21 cis-monounsaturated alkenyl; and (b) a nonsteroidal analgesic selected from the group consisting of ibuprofen, naproxen, ketoprofen, fenaprofen, suprofen, flurbiprofen, benoxaprofen, perprofen, and carprofen; wherein the weight ratio of (a):(b) is from about 20:1 to about 1:20.
Claim 13
Independent Claim
109 words
A method for providing analgesia in humans and lower animals which comprises administering concurrently to a human or lower animal in need of such treatment a safe and effective amount of: (a) a capsaicinoid analgesic compound of the general formula: ##STR12## wherein R 1 is selected from the group consisting of OH and OCH 3 , X is selected from the group consisting of ##STR13## and R is a C 16 -C 21 cis-monounsaturated alkenyl; and (b) a nonsteroidal analgesic selected from the group consisting of ibuprofen, naproxen, ketoprofen, fenaprofen, suprofen, flurbiprofen, benoxaprofen, perprofen, and carprofen; wherein the weight ratio of (a):(b) is from about 20:1 to about 1:20.
Claim 14
Dependent Claim
11 words
A method according to claim 11, wherein the non-steroidal is ibuprofen.
Claim 15
Dependent Claim
30 words
A method according to claim 12, wherein the capsaicinoid is N-vanillyl-9Z-octadecenamide, the nonsteroidal is ibuprofen, and the weight ratio of N-vanillyl-9Z-octadecenamide to ibuprofen is from about 5:1 to about 1:5.
Claim 16
Dependent Claim
12 words
A method according to claim 11, wherein the composition is administered orally.
Claim 17
Dependent Claim
12 words
A method according to claim 11, wherein the composition is administered topically.
References Cited (Backward Citations)
US3060091A
Cited
US3110650A
Cited
US3106513A
Cited
US4083981A
Cited
US4269828A
Cited
US4275059A
Cited
US4216212A
Cited
US4264582A
Cited
US4282214A
Cited
US4238508A
Cited
US4315936A
Cited
US4379789A
Cited
US4313958A
Cited
US4401663A
Cited
US4424205A
Cited
US4404210A
Cited
US4407805A
Cited
US4407804A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1990-07-20 | 1991-01-19 | 1991-07-21 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1994-07-20 | 1995-01-19 | 1995-07-21 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1998-07-20 | 1999-01-19 | 1999-07-21 | $7700.00 | Window Closed / Lapsed |